ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.

Slides:



Advertisements
Similar presentations
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of.
Advertisements

August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
ISAR-REACT 2 ESC 2007 M. Seyfarth, A. Kastrati, J. Mehilli, F.-J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, J. Pache, J. Dirschinger, P. B. Berger,
Assessment of the best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Ongoing Necrosis ALBION.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
Can we prevent stent restenosis after coronary stent implantation
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
S. Banai, M.D. Loading dose with Clopidogrel before PCI How high should we go? Shmuel Banai, MD Director, Interventional Cardiology Tel Aviv Medical Center.
ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
ARMYDA-CIN Trial [Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy]
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Upstream statin in ACS : Do we need to reload our patient? By Ashraf Reda, MD, FESC Prof and head of cardiology dep.-Menofiya university President of EGYBAC.
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Germano Di Sciascio, MD, FACC, FESC Professor & Chairman of.
Can we protect patients undergoing percutaneous coronary intervention better? Beneficial effects of short- and long-term trimetazidine MR therapy in patients.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
STATINS PRE-PCI: A Prospective, Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina Josef VESELKA CardioVascular Center.
C. Michael Gibson, MS, MD Beth Israel Deaconess Medical Center Boston, MA The Benefit of Statin Therapy Before and After Coronary Revascularization.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
ARNO TRIAL (Antithrombotic Regimens aNd Outcome) A RANDOMIZED TRIAL COMPARING BIVALIRUDIN WITH UNFRACTIONED HEPARIN IN PATIENTS UNDERGOING ELECTIVE PCI.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
The American College of Cardiology Presented by Dr. Adnan Kastrati
Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.
On behalf of all principal COMPARE II investigators:
Introduction We have previously reported a significant incidence of clopidogrel resistance in patients post-elective coronary stenting treated with a standard.
RAAS Blockade: Focus on ACEI
Atorvastatin for Reduction of Myocardial Damage During Angioplasty
Giuseppe Biondi Zoccai, MD
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES
American Heart Association Presented by Dr. Julinda Mehilli
Impact of Platelet Reactivity Following Clopidogrel Administration
Erasmus MC, Thoraxcenter
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Maintenance of Long-Term Clinical Benefit with
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Section C: Clinical trial update: Oral antiplatelet therapy
Presentation transcript:

ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating influence on PCI outcome of additional 600 mg clopidogrel load in patients on chronic therapy - “ARMYDA-Reload” Principal Investigators: Giuseppe Patti, Vincenzo Pasceri, Giuseppe Colonna Investigators: Antonio Montinaro, Leonardo Lassandro Pepe, Antonio Tondo, Laura Gatto, Fabio Mangiacapra, Francesco Ciccirillo, Andrea D’Ambrosio, Annunziata Nusca, Giordano Dicuonzo, Gennaro Sardella, Bibi NGuyen Chairman: Germano Di Sciascio

(%) ARMYDA-2 RESULTS Primary end-point 30-day Death, MI, TVR Circulation 2005;111: P= % 12%

Antiplatet effects of a 600 mg load on chronic clopidogrel Rx ADP (5  mol/L)-induced aggregation, % 600 mg clopidogrel Before load After load No prior clopidogrel N=20 N=20 Chronic clopidogrel N=20 N=20 P<0.001 P<0.001 P<0.001 Kastrati et al. Circulation 2004

PCI “reload” arm N= Patients on clopidogrel therapy with Stable angina or NSTE ACS undergoing coronary angiography Primary end point: Death, MI*, TVR 2 nd and 3 rd blood sample at 8 and 24 hours 30days Randomization Angiography Clopidogrel 600 mg re-loading ‡ N= st blood sample before PCI - CK-MB, troponin-I, myoglobin, CRP ARMYDA-4: Study design Placebo ‡ N= 234 PCI - placebo arm N= Hours pre-PCI * MI = >3 times UNL CK-MB ‡ On top of chronic therapy Medical Rx N= 62 CABG N= 42 N= 360

Inclusion criteria - Pts on chronic therapy with clopidogrel (> 10 days) with stable angina or non-STE ACS undergoing PCI Exclusion criteria - Primary PCI - Platelet count <70x10 3 /ml - Pts at high risk of bleeding - Coronary by-pass grafting in the previous 3 months ARMYDA-4

STUDY ENDPOINTS Primary endpoint  30-day incidence of death, MI, TVR (MI definition: post-procedural increase of CK-MB >3 times above UNL in patients with normal baseline levels of creatine kinase-MB) Secondary endpoints Any postprocedural increase of markers of myocardial injury above UNL (CK-MB, troponin I, myoglobin) Mean peak values of CK-MB, troponin I and myoglobin after intervention Occurrence of any vascular/hemorragic complications “Point of care” evaluation of platelet reactivity at different time points in the two arms

Age (yrs) Male sex (%) Diabetes mellitus (%) Hypertension (%) Hypercolesterolemia (%) Current smokers (%) Previous MI (%) Previous PCI (%) Previous CABG (%) Clinical pattern (%) Non STE ACS Multivessel disease (%) LVEF (%) Aspirin (%) Statins (%) 600 mg Clopidogrel reload N=180 Placebo N=180 P 65± (78) 56 (31) 136 (75) 142 (79) 36 (20) 54 (30) 88 (49) 16 (9) 67 (37) 78 (43) 55±7 180 (100) 171 (95) 65± (77) 59 (33) 149 (83) 142 (79) 34 (19) 57 (31) 77 (43) 13 (7) 70 (39) 67 (37) 55±7 180 (100) 168 (93) ARMYDA-4 Clinical Characteristics N=360 pts

P Vessel treated (%) Left main LAD LCx Right coronary SVG Chronic total occl. (>3 mo.)(%) Restenotic lesions (%) Lesion type B2/C (%) Multivessel intervention (%) Type of intervention (%) Balloon only Stent DES (%) 5 (2) 82 (40) 46 (22) 70 (34) 5 (2) 18 (10) 13 (7) 123 (59) 28 (15) 18 (10) 162 (90) 76 (42) 4 (2) 86 (40) 47 (22) 67 (31) 8 (3) 10 (5) 13 (7) 130 (61) 33 (18) 14 (8) 166 (92) 78 (43) mg Clopidogrel reload N=180 Placebo N=180 ARMYDA – 4 Trial Procedural features

ARMYDA-4 Trial Composite primary end-point (30-day death, MI, TVR) % 7 8 P=0.96

ARMYDA-4 Trial Individual events at 30 days 600 mg Clopidogrel reload Placebo 7 8 %

ARMYDA-4 Trial Secondary end points Post-procedural elevation of markers of myocardial injury above UNL % of patients 600 mg Clopidogrel re load Placebo P=0.98 P=

ARMYDA-4 Trial Secondary end points Post-PCI peak levels of markers of myocardial injury (CK-MB and Troponin-I) 600 mg Clopidogrel reload Placebo Peak value of CK-MB (ng/ml) Peak value of Tn-I (ng/ml) 5.6±7.55.3± ± ±0.87 P=0.90 CK-MB P= mg Clopidogrel reload Placebo Troponin-I 0.39±1.1

ARMYDA-4 Trial Secondary end points Bleeding rates 600 mg Clopidogrel reload Placebo %

211±66 166±60 217±66 183±68 177±71 153±65 208±68 173±69 199±64 178±62 174±65 146±63 Base Study PCI 2 hrs 6 hrs 24 hrs Drug Platelet reaction units (PRU) ARMYDA-4: Platelet aggregometry * P=0.2 * By Accumetrics Placebo Clopidogrel 600 mg Placebo Further load

 Results of the ARMYDA-4 trial indicate that a pre-PCI 600 mg loading dose does not confer additional clinical benefit in patients already receiving chronic therapy with clopidogrel  Point of care aggregometry testing shows no significant differences in platelet reactivity in the 2 arms  No increased bleeding risk is observed in the “reload” approach  Patients on chronic clopidogrel therapy can safely undergo PCI without need of further reload CONCLUSIONS

Several studies have demonstrated beneficial clinical effects of a 600 mg clopidogrel loading dose in patients undergoing percutaneous coronary intervention (PCI). Laboratory evidence suggests that an additional pre-PCI 600 mg loading further decreases platelet aggregation in patients already on chronic treatment with clopidogrel. However, there are no clinical data on the safety and efficacy of this strategy. BACKGROUND